Literature DB >> 17876722

A severity scoring tool to assess the neurological features of neuronopathic Gaucher disease.

E H Davies1, R Surtees, C DeVile, I Schoon, A Vellodi.   

Abstract

Type III Gaucher disease is one of the three recognized subtypes of Gaucher disease, an inherited deficiency of lysosomal glucocerebrosidase. Phenotypically there is a wide spectrum of visceral and neurological manifestations. Enzyme replacement is effective in managing the visceral disease; however, the neurological manifestations remain a more challenging obstacle. There is an unfulfilled need to reliably monitor neurological disease and its response to treatment. A severity scoring tool was developed through neurological domain identification, item generation and tool formation. Domain identification was established based on a retrospective single centre study (n = 15) and a systematic review of publications. Forty-seven patients with neuronopathic Gaucher disease were then assessed using the tool to establish the clinical and statistical reliability of each domain. Judgement quantification of the tool was established through a process of content validity involving five European experts. Content validity is considered to be most effective when undertaken systematically. Concurrent validity and feasibility of the tool was also highlighted. This process allowed a revised and validated version of the tool to be developed.

Entities:  

Mesh:

Year:  2007        PMID: 17876722     DOI: 10.1007/s10545-007-0595-x

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  20 in total

1.  Gaucher disease--Norrbottnian type. I. General clinical description.

Authors:  S Dreborg; A Erikson; B Hagberg
Journal:  Eur J Pediatr       Date:  1980-03       Impact factor: 3.183

2.  Enzyme replacement therapy for Gaucher disease in Australia.

Authors:  J Goldblatt; J Szer; J M Fletcher; J McGill; J A Rowell; M Wilson
Journal:  Intern Med J       Date:  2005-03       Impact factor: 2.048

3.  Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations.

Authors:  Robert Steinfeld; Peter Heim; Henning von Gregory; Kerstin Meyer; Kurt Ullrich; Hans H Goebel; Alfried Kohlschütter
Journal:  Am J Med Genet       Date:  2002-11-01

4.  Clinical and genetic studies of Japanese homozygotes for the Gaucher disease L444P mutation.

Authors:  H Ida; O M Rennert; K Iwasawa; M Kobayashi; Y Eto
Journal:  Hum Genet       Date:  1999 Jul-Aug       Impact factor: 4.132

5.  Myoclonic epilepsy in Gaucher disease: genotype-phenotype insights from a rare patient subgroup.

Authors:  Joseph K Park; Eduard Orvisky; Nahid Tayebi; Christine Kaneski; Mary E Lamarca; Barbara K Stubblefield; Brian M Martin; Raphael Schiffmann; Ellen Sidransky
Journal:  Pediatr Res       Date:  2003-03       Impact factor: 3.756

6.  Gaucher's disease variant characterised by progressive calcification of heart valves and unique genotype.

Authors:  A Abrahamov; D Elstein; V Gross-Tsur; B Farber; Y Glaser; I Hadas-Halpern; S Ronen; M Tafakjdi; M Horowitz; A Zimran
Journal:  Lancet       Date:  1995-10-14       Impact factor: 79.321

7.  Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.

Authors:  Anders Erikson; Håkan Forsberg; Magnus Nilsson; Marianne Aström; Jan-Eric Månsson
Journal:  Acta Paediatr       Date:  2006-03       Impact factor: 2.299

8.  Enzyme infusion therapy of the Norrbottnian (type 3) Gaucher disease.

Authors:  A Erikson; M Aström; J E Månsson
Journal:  Neuropediatrics       Date:  1995-08       Impact factor: 1.947

9.  The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy.

Authors:  C Whybra; C Kampmann; F Krummenauer; M Ries; E Mengel; E Miebach; F Baehner; K Kim; M Bajbouj; A Schwarting; A Gal; M Beck
Journal:  Clin Genet       Date:  2004-04       Impact factor: 4.438

10.  Characterization of neuronopathic Gaucher disease among ethnic Poles.

Authors:  Anna Tylki-Szymañska; Mehdi Keddache; Gregory A Grabowski
Journal:  Genet Med       Date:  2006-01       Impact factor: 8.822

View more
  17 in total

1.  Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool.

Authors:  Elin Haf Davies; Eugen Mengel; Anna Tylki-Szymanska; G Kleinotiene; Joerg Reinke; Ashok Vellodi
Journal:  J Inherit Metab Dis       Date:  2011-05-28       Impact factor: 4.982

Review 2.  Neuropathic Gaucher disease.

Authors:  Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

3.  Brain white matter abnormalities in paediatric Gaucher Type I and Type III using diffusion tensor imaging.

Authors:  Elin Haf Davies; Kiran K Seunarine; Tina Banks; Chris A Clark; Ashok Vellodi
Journal:  J Inherit Metab Dis       Date:  2011-02-12       Impact factor: 4.982

Review 4.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

Review 5.  Type 2 Gaucher disease: phenotypic variation and genotypic heterogeneity.

Authors:  N Gupta; I M Oppenheim; E F Kauvar; N Tayebi; E Sidransky
Journal:  Blood Cells Mol Dis       Date:  2010-09-28       Impact factor: 3.039

Review 6.  Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

Authors:  E H Davies; A Erikson; T Collin-Histed; E Mengel; A Tylki-Szymanska; A Vellodi
Journal:  J Inherit Metab Dis       Date:  2007-11-12       Impact factor: 4.982

7.  Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry.

Authors:  Anna Tylki-Szymańska; Ashok Vellodi; Amal El-Beshlawy; J Alexander Cole; Edwin Kolodny
Journal:  J Inherit Metab Dis       Date:  2010-01-19       Impact factor: 4.982

8.  Management of neuronopathic Gaucher disease: revised recommendations.

Authors:  A Vellodi; A Tylki-Szymanska; E H Davies; E Kolodny; B Bembi; T Collin-Histed; E Mengel; A Erikson; R Schiffmann
Journal:  J Inherit Metab Dis       Date:  2009-08-05       Impact factor: 4.982

9.  The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Authors:  Dinesh Khanna; Veronica J Berrocal; Edward H Giannini; James R Seibold; Peter A Merkel; Maureen D Mayes; Murray Baron; Philip J Clements; Virginia Steen; Shervin Assassi; Elena Schiopu; Kristine Phillips; Robert W Simms; Yannick Allanore; Christopher P Denton; Oliver Distler; Sindhu R Johnson; Marco Matucci-Cerinic; Janet E Pope; Susanna M Proudman; Jeffrey Siegel; Weng Kee Wong; Athol U Wells; Daniel E Furst
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-02       Impact factor: 4.794

10.  The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis.

Authors:  Dinesh Khanna; Veronica J Berrocal; Edward H Giannini; James R Seibold; Peter A Merkel; Maureen D Mayes; Murray Baron; Philip J Clements; Virginia Steen; Shervin Assassi; Elena Schiopu; Kristine Phillips; Robert W Simms; Yannick Allanore; Christopher P Denton; Oliver Distler; Sindhu R Johnson; Marco Matucci-Cerinic; Janet E Pope; Susanna M Proudman; Jeffrey Siegel; Weng Kee Wong; Athol U Wells; Daniel E Furst
Journal:  Arthritis Rheumatol       Date:  2016-02       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.